Controlling cell fate by bone morphogenetic protein receptors

Molecular and Cellular Endocrinology

Volumn 211, Issue 1-2, 2003, Pages 105-113

  Ten Dijke, Peter ^a   Korchynskyi, Olexander ^a   Valdimarsdottir, Gudrun ^a   Goumans, Marie José ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BMP; Id1; Serine threonine kinase receptor; Signal transduction; Smad; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR; SMAD PROTEIN;

CELL DIFFERENTIATION; CELL FATE; CELL MIGRATION; CELL TYPE; CONFERENCE PAPER; ENDOTHELIUM CELL; GENE ACTIVATION; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; MESENCHYME; MORPHOGENESIS; MUSCLE DEVELOPMENT; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0345377805     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.09.016     Document Type: Conference Paper

References (104)

1. Abdollah S., Macias-Silva M., Tsukazaki T., Hayashi H., Attisano L., Wrana J.L. TβRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272:1997;27678-27685.
2. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β Nat. Cell Biol. 8:2002;599-604.
3. Afrakhte M., Morén A., Jossan S., Itoh S., Sampath K., Westermark B., Heldin C.H., Heldin N.E., ten Dijke P. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem. Biophys. Res. Commun. 249:1998;505-511.
4. Ahn K., Mishina Y., Hanks M.C., Behringer R.R., Crenshaw E.B. III BMPR-IA signaling is required for the formation of the apical ectodermal ridge and dorsal-ventral patterning of the limb. Development. 128:2001;4449-4461.
5. Attisano L., Wrana J.L. Signal transduction by the TGF-β superfamily. Science. 296:2002;1646-1647.
6. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., Van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Vickery B., Foernzler D., Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10:2001;537-543.
7. Baur S.T., Mai J.J., Dymecki S.M. Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity. Development. 127:2000;605-619.
8. Beppu H., Kawabata M., Hamamoto T., Chytil A., Minowa O., Noda T., Miyazono K. BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev. Biol. 221:2000;249-258.
9. Brunet L.J., McMahon J.A., McMahon A.P., Harland R.M. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science. 280:1998;1455-1457.
10. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68:2001;577-589.
11. Calonge M.J., Massagué J. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-β antiproliferative responses in colon cancer cells. J. Biol. Chem. 274:1999;33637-33643.
12. Carcámo J., Weis F.M., Ventura F., Wieser R., Wrana J.L., Attisano L., Massagué J. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol. Cell Biol. 14:1994;3810-3821.
13. Chen Y.G., Massagué J. Smad1 recognition and activation by the ALK-1 group of transforming growth factor-β family receptors. J. Biol. Chem. 274:1999;3672-3677.
14. Clarke T.R., Hoshiya Y., Yi S.E., Liu X., Lyons K.M., Donahoe P.K. Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK-2 and induces SMAD6 expression. Mol. Endocrinol. 15:2001;946-959.
15. Clement J.H., Marr N., Meissner A., Schwalbe M., Sebald W., Kliche K.O., Hoffken K., Wolfl S. Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J. Cancer Res. Clin. Oncol. 126:2000;271-279.
16. Cunningham N.S., Paralkar V., Reddi A.H. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor β 1 mRNA expression. Proc. Natl. Acad. Sci. U.S.A. 89:1992;11740-11744.
17. Dennler S., Itoh S., Vivien D., ten Dijke P., Huet S., Gauthier J.M. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:1998;3091-3100.
18. Derynck R., Zhang Y., Feng X.H. Smads: transcriptional activators of TGF-β responses. Cell. 95:1998;737-740.
19. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., Miyazono K. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276:2001;12477-12480.
20. Feng X.H., Derynck R. A kinase subdomain of transforming growth factor-β(TGF-β) type I receptor determines the TGF-β intracellular signaling specificity. EMBO J. 16:1997;3912-3923.
21. Gaussin V., Van de Putte T., Mishina Y., Hanks M.C., Zwijsen A., Huylebroeck D., Behringer R.R., Schneider M.D. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK-3. Proc. Natl. Acad. Sci. U.S.A. 99:2002;2878-2883.
22. Gouedard L., Chen Y.G., Thevenet L., Racine C., Borie S., Lamarre I., Josso N., Massagué J., di Clemente N. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J. Biol. Chem. 275:2000;27973-27978.
23. Goumans M.J., Mummery C. Functional analysis of the TGF-β receptor/Smad pathway through gene ablation in mice. Int. J. Dev. Biol. 44:2000;253-265.
24. Gu Z., Reynolds E.M., Song J., Lei H., Feijen A., Yu L., He W., MacLaughlin D.T., van den Eijnden-van R., Donahoe P.K., Li E. The type I serine/threonine kinase receptor ActR-IA (ALK-2) is required for gastrulation of the mouse embryo. Development. 126:1999;2551-2561.
25. Guha U., Gomes W.A., Kobayashi T., Pestell R.G., Kessler J.A. In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb. Dev. Biol. 249:2002;108-120.
26. Hanyu A., Ishidou Y., Ebisawa T., Shimanuki T., Imamura T., Miyazono K. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. J. Cell Biol. 155:2001;1017-1027.
27. Hata A., Lagna G., Massagué J., Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 12:1998;186-197.
28. Hata A., Seoane J., Lagna G., Montalvo E., Hemmati-Brivanlou A., Massagué J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell. 100:2000;229-240.
29. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone M.A. Jr., Wrana J.L., Falb D. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell. 89:1997;1165-1173.
30. Henningfeld K.A., Rastegar S., Adler G., Knochel W. Smad1 and Smad4 are components of the bone morphogenetic protein-4 (BMP-4)-induced transcription complex of the Xvent-2B promoter. J. Biol. Chem. 275:2000;21827-21835.
31. Hollnagel A., Oehlmann V., Heymer J., Ruther U., Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J. Biol. Chem. 274:1999;19838-19845.
32. Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 28:2001;184-187.
33. Hogan B.L. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 4:1996;432-438.
34. Hsu D.R., Economides A.N., Wang X., Eimon P.M., Harland R.M. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol. Cell. 1:1998;673-683.
35. Huse M., Chen Y.G., Massagué J., Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF-β receptor in complex with FKBP12. Cell. 96:1999;425-436.
36. Iemura S., Yamamoto T.S., Takagi C., Uchiyama H., Natsume T., Shimasaki S., Sugino H., Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9337-9342.
37. Imamura T., Takase M., Nishihara A., Oeda E., Hanai J., Kawabata M., Miyazono K. Smad6 inhibits signalling by the TGF-β superfamily. Nature. 389:1997;622-626.
38. Ishida W., Hamamoto T., Kusanagi K., Yagi K., Kawabata M., Takehara K., Sampath T.K., Kato M., Miyazono K. Smad6 is a Smad1/5-induced smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J. Biol. Chem. 275:2000;6075-6079.
39. Ishisaki A., Yamato K., Nakao A., Nonaka K., Ohguchi M., ten Dijke P., Nishihara T. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J. Biol. Chem. 273:1998;24293-24296.
40. Ishisaki A., Yamato K., Hashimoto S., Nakao A., Tamaki K., Nonaka K., ten Dijke P., Sugino H., Nishihara T. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J. Biol. Chem. 274:1999;13637-13642.
41. Itoh S., Itoh F., Goumans M.-J., ten Dijke P. Signaling of transforming growth factor β family members through Smad proteins. Eur. J. Biochem. 267:2000;6954-6967.
42. Jamin S.P., Arango N.A., Mishina Y., Hanks M.C., Behringer R.R. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat. Genet. 32:2002;408-410.
43. Janknecht R., Wells N.J., Hunter T. TGF-β-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev. 12:1998;2114-2119.
44. Jen Y., Weintraub H., Benezra R. Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev. 6:1992;1466-1479.
45. Jonk L.J., Itoh S., Heldin C.H., ten Dijke P., Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273:1998;21145-21152.
46. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., Rosen V., Wozney J.M., Fujisawa-Sehara A., Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127:1994;1755-1766.
47. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., Wrana J.L. Smad7 Binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol. Cell. 6:2000;1365-1375.
48. Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K. Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J. 17:1998;4056-4065.
49. Kirsch T., Sebald W., Dreyer M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 7:2000;492-496.
50. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., Olson C.A., Pecquet A.L., Ventura F., Grant R.A. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell Biol. 14:1994;5961-5974.
51. Korchynskyi O., ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem. 277:2002;4883-4891.
52. Korchynskyi, O., ten Dijke, P., 2002. Bone morphogenetic prptein receptors and their nuclear effectors in bone formation. In: Vukicevic, S., Sampath, T.K. (Eds.), Bone Morphogenetyic Proteins, Bikhauser Verlag Basel, Switzerland, pp. 31-60.
53. Kretzschmar M., Doody J., Massagué J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature. 389:1997;618-622.
54. Kretzschmar M., Liu F., Hata A., Doody J., Massagué J. The TGF-β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11:1997;984-995.
55. Kretzschmar M., Doody J., Timokhina I., Massagué J. A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev. 13:1999;804-816.
56. Lebrun J.J., Takabe K., Chen Y., Vale W. Roles of pathway-specific and inhibitory Smads in activin receptor signaling. Mol. Endocrinol. 13:1999;15-23.
57. Lin H.Y., Wang X.F., Ng-Eaton E., Weinberg R.A., Lodish H.F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell. 68:1992;775-785.
58. Lin X., Liang M., Feng X.H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J. Biol. Chem. 275:2000;36818-36822.
59. Liu F., Ventura F., Doody J., Massagué J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell Biol. 15:1995;3479-3486.
60. Lopez-Rovira T., Chalaux E., Massagué J., Rosa J.L., Ventura F. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J. Biol. Chem. 277:2002;3176-3185.
61. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K., Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 401:1999;670-677.
62. Macias-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK-2. J. Biol. Chem. 273:1998;25628-25636.
63. Massagué J. TGF-β signal transduction. Annu. Rev. Biochem. 67:1998;753-791.
64. Mathews L.S., Vale W.W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell. 65:1991;973-982.
65. Matzuk M.M., Kumar T.R., Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature. 374:1995;356-360.
66. Mishina Y., Suzuki A., Ueno N., Behringer R.R. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 9:1995;3027-3037.
67. Moldes M., Lasnier F., Feve B., Pairault J., Djian P. Id3 prevents differentiation of preadipose cells. Mol. Cell Biol. 17:1997;1796-1804.
68. Mulsant P., Lecerf F., Fabre S., Schibler L., Monget P., Lanneluc I., Pisselet C., Riquet J., Monniaux D., Callebaut I., Cribiu E., Thimonier J., Teyssier J., Bodin L., Cognie Y., Chitour N., Elsen J.M. Mutation in bone morphogenetic protein receptor-IB is associated with increased ovulation rate in Booroola Merino ewes. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5104-5109.
69. Nakao A., Afrakhte M., Morén A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H., ten Dijke P. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature. 389:1997;631-635.
70. Nakashima K., Takizawa T., Ochiai W., Yanagisawa M., Hisatsune T., Nakafuku M., Miyazono K., Kishimoto T., Kageyama R., Taga T. BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to astrocytogenesis. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5868-5873.
71. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makishima F., Yamaguchi A., Yamashita H., Enomoto S., Miyazono K. Identification of types I and II serine/threonine kinase receptors for growth/differentiation factor-5. J. Biol. Chem. 271:1996;21345-21352.
72. Norton J.D., Deed R.W., Craggs G., Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 8:1998;58-65.
73. Ogata T., Wozney J.M., Benezra R., Noda M. Bone morphogenetic protein 2 transiently enhances expression of a gene, inhibitor of differentiation (Id), encoding a helix-loop-helix molecule in osteoblast-like cells. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9219-9222.
74. Oh S.P., Li E. The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse. Genes Dev. 11:1997;1812-1826.
75. Park G.T., Morasso M.I. Bone morphogenetic protein-2 (BMP-2) transactivates Dlx3 through Smad1 and Smad4: alternative mode for Dlx3 induction in mouse keratinocytes. Nucl. Acids Res. 30:2002;515-522.
76. Persson U., Izumi H., Souchelnytskyi S., Itoh S., Grimsby S., Engstrom U., Heldin C.H., Funa K., ten Dijke P. The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 434:1998;83-87.
77. Piccolo S., Sasai Y., Lu B., De Robertis E.M. Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell. 86:1996;589-598.
78. Reddi A.H. Bone morphogenetic proteins: from basic science to clinical applications. J. Bone Joint Surg. Am. 83-A(Suppl. 1):2001;S1-S6.
79. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., Heldin C.H., Miyazono K. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. U.S.A. 92:1995;7632-7636.
80. Shi Y., Wang Y.F., Jayaraman L., Yang H., Massagué J., Pavletich N.P. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling. Cell. 94:1998;585-594.
81. Song J., Oh S.P., Schrewe H., Nomura M., Lei H., Okano M., Gridley T., Li E. The type II activin receptors are essential for egg cylinder growth, gastrulation, and rostral head development in mice. Dev. Biol. 213:1999;157-169.
82. Souchelnytskyi S., Tamaki K., Engstrom U., Wernstedt C., ten Dijke P., Heldin C.H. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J. Biol. Chem. 272:1997;28107-28115.
83. Souchelnytskyi S., Nakayama T., Nakao A., Morén A., Heldin C.H., Christian J.L., ten Dijke P. Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. J. Biol. Chem. 273:1998;25364-25370.
84. Storm E.E., Kingsley D.M. Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family. Development. 122:1996;3969-3979.
85. Storm E.E., Kingsley D.M. GDF5 coordinates bone and joint formation during digit development. Dev. Biol. 209:1999;11-27.
86. Takase M., Imamura T., Sampath T.K., Takeda K., Ichijo H., Miyazono K., Kawabata M. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem. Biophys. Res. Commun. 244:1998;26-29.
87. ten Dijke P., Yamashita H., Ichijo H., Franzen P., Laiho M., Miyazono K., Heldin C.H. Characterization of type I receptors for transforming growth factor-β and activin. Science. 264:1994;101-104.
88. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J., Wheeler L., Higenbottam T., Gibbs J.S., Egan J., Crozier A., Peacock A., Allcock R., Corris P., Loyd J.E., Trembath R.C., Nichols W.C. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J. Med. Genet. 37:2000;741-745.
89. Tsumaki N., Nakase T., Miyaji T., Kakiuchi M., Kimura T., Ochi T., Yoshikawa H. Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. J. Bone Miner. Res. 17:2002;898-906.
90. Urist M.R. Bone: formation by autoinduction. Science. 150:1965;893-899.
91. Valdimarsdottir G., Goumans M.J., Rosendahl A., Brugman M., Itoh S., Lebrin F., Sideras P., ten Dijke P. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 106:2002;2263-2270.
92. Visser J.A., Olaso R., Verhoef-Post M., Kramer P., Themmen A.P., Ingraham H.A. The serine/threonine transmembrane receptor ALK-2 mediates Mullerian inhibiting substance signaling. Mol. Endocrinol. 15:2001;936-945.
93. Vukicevic S., Luyten F.P., Reddi A.H. Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc. Natl. Acad. Sci. U.S.A. 86:1989;8793-8797.
94. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science. 242:1988;1528-1534.
95. Wrana J.L., Attisano L., Carcámo J., Zentella A., Doody J., Laiho M., Wang X.F., Massagué J. TGF-β signals through a heteromeric protein kinase receptor complex. Cell. 71:1992;1003-1014.
96. Wrana J.L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-β receptor. Nature. 370:1994;341-347.
97. Yamaguchi A., Katagiri T., Ikeda T., Wozney J.M., Rosen V., Wang E.A., Kahn A.J., Suda T., Yoshiki S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 113:1991;681-687.
98. Yamashita H., ten Dijke P., Huylebroeck D., Sampath T.K., Andries M., Smith J.C., Heldin C.H., Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol. 130:1995;217-226.
99. Yi S.E., LaPolt P.S., Yoon B.S., Chen J.Y., Lu J.K., Lyons K.M. The type I BMP receptor BmprIB is essential for female reproductive function. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7994-7999.
100. Zawel L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., Kern S.E. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell. 1:1998;611-617.
101. Zhang Y., Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 9:1999;274-279.
102. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 98:2001;974-979.
103. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 400:1999;687-693.
104. Zimmerman L.B., Jesus-Escobar J.M., Harland R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell. 86:1996;599-606.